Literature DB >> 11830254

The PXR crystal structure: the end of the beginning.

Sean Ekins, Erin Schuetz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11830254     DOI： 10.1016/s0165-6147(02)01977-6

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


× No keyword cloud information.
  7 in total

Review 1.  A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta.

Authors:  Sean Ekins; Leonid Mirny; Erin G Schuetz
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

2.  Identification of clinically used drugs that activate pregnane X receptors.

Authors:  Sunita J Shukla; Srilatha Sakamuru; Ruili Huang; Timothy A Moeller; Paul Shinn; Danielle Vanleer; Douglas S Auld; Christopher P Austin; Menghang Xia
Journal:  Drug Metab Dispos       Date:  2010-10-21       Impact factor: 3.922

Review 3.  The Roles of Xenobiotic Receptors: Beyond Chemical Disposition.

Authors:  Bryan Mackowiak; Jessica Hodge; Sydney Stern; Hongbing Wang
Journal:  Drug Metab Dispos       Date:  2018-05-14       Impact factor: 3.922

Review 4.  Neurosteroid regulation of central nervous system development.

Authors:  Synthia H Mellon
Journal:  Pharmacol Ther       Date:  2007-06-16       Impact factor: 12.310

5.  Effect of Hexadecyl Azelaoyl Phosphatidylcholine on Cardiomyocyte Apoptosis in Myocardial Ischemia-Reperfusion Injury: A Hypothesis.

Authors:  Limin Feng; Wennan Liu; Jianzhou Yang; Qing Wang; Shiwu Wen
Journal:  Med Sci Monit       Date:  2018-04-30

6.  Discrepancy in interactions and conformational dynamics of pregnane X receptor (PXR) bound to an agonist and a novel competitive antagonist.

Authors:  Azam Rashidian; Enni-Kaisa Mustonen; Thales Kronenberger; Matthias Schwab; Oliver Burk; Stefan A Laufer; Tatu Pantsar
Journal:  Comput Struct Biotechnol J       Date:  2022-06-13       Impact factor: 6.155

7.  A Comprehensive Evaluation of Sdox, a Promising H2S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors.

Authors:  Petko Alov; Merilin Al Sharif; Denitsa Aluani; Konstantin Chegaev; Jelena Dinic; Aleksandra Divac Rankov; Miguel X Fernandes; Fabio Fusi; Alfonso T García-Sosa; Risto Juvonen; Magdalena Kondeva-Burdina; José M Padrón; Ilza Pajeva; Tania Pencheva; Adrián Puerta; Hannu Raunio; Chiara Riganti; Ivanka Tsakovska; Virginia Tzankova; Yordan Yordanov; Simona Saponara
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.